FilingReader Intelligence
Bloomage Biotechnology sees revenue dip, reassures on long-term growth
June 30, 2025 at 05:15 PM UTC•By FilingReader AI
** Bloomage Biotechnology Corporation (SSE:688363) reported a 11.61% dip in revenue to CNY 5.37 billion for 2024. While raw material and medical end businesses saw positive growth, a strategic shift in the company's skin care line was a primary factor in the decline. Net profit attributable to shareholders fell 70.59% to CNY 174 million due to these changes.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SSE:688363•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Bloomage Biotechnology Corporation publishes news
Free account required • Unsubscribe anytime